| abstract |
Provided herein are agents that bind to binding domain I of LRP1 and mimic the activity of prosaposin in stimulating Tsp-1. Furthermore, the present specification provides an agent that inhibits the function of PRSS2 (for example, the ability to suppress Tsp-1) by inhibiting the binding of the protease serine 2 (PRSS2) to LRP1. Methods of using these agents in treating cancer are also provided. |